Overall world revenue for the Pharma Contract Sales Market: In terms of value the market will surpass US$13.0 billion in 2025, the work calculates. The publisher predicts strong revenue growth through to 2035. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
CRO-CSO Integration Accelerates End-to-End Commercialisation Models
Pharmaceutical companies are increasingly turning to service providers that can bridge the gap between clinical development and commercial execution. The consolidation of CRO and CSO functions allows for smoother transition from trials to market launch, reducing delays, managing risk, and offering a single point of accountability. This model aligns particularly well with today's global drug launches, where speed, compliance, and scale are essential. A strong example comes from 26 August 2025, when EVERSANA merged with Waltz Health to form a unified healthcare platform. By integrating Waltz's drug-price marketplace and direct-to-payer model with EVERSANA's commercialization capabilities, the partnership strengthens drug access strategies while enhancing value delivery. Similarly, on 25 March 2025, Syneos Health signed a Master Commercial Services Agreement with Scienture Holdings, positioning itself as Scienture's dedicated Contract Sales Organisation to manage outsourced field and digital engagement services. This highlights how large players are consolidating their service offerings to provide clients with seamless end-to-end capabilities, reinforcing the global trend toward integrated CRO-CSO platforms.What would be the Impact of US Trade Tariffs on the Global Pharma Contract Sales Market?
U.S. trade tariffs on pharmaceutical inputs and medical components, particularly those sourced from China, are increasing cost pressures and reshaping how global pharma companies think about commercial models. As margins tighten, originator companies are under greater pressure to reduce fixed commercial overheads, which can accelerate the shift from large in-house sales teams to variable cost, outsourced models. This creates opportunities for Contract Sales Organisations (CSOs) that can offer leaner field forces, more targeted deployment, and strong digital engagement to maintain reach at lower cost. For example, a U.S. biotech facing higher landed costs on Chinese APIs may decide to outsource its secondary care salesforce for a mature brand to a CSO, freeing internal resources to protect launch budgets for newer, higher value products. Tariffs are also driving supply chain diversification and rerouting, which adds complexity to market access, channel management, and launch planning - areas where CSOs and integrated commercial partners can step in. As companies split sourcing across multiple countries or move some manufacturing closer to end markets, they must navigate different payer systems, distributor structures, and regulatory expectations, often with limited internal local presence. CSOs that combine sales execution with market access support, trade-channel coordination, and data driven territory planning are well placed to manage this complexity. For instance, a multinational shifting part of its API sourcing from China to India and Eastern Europe might rely on regional CSO partners in Europe and Asia to handle hospital engagement, explain any supply or pricing shifts to stakeholders, and protect market share during the transition triggered by tariff changes.Key Questions Answered
- How is the pharma contract sales market evolving?
- What is driving and restraining the pharma contract sales market?
- How will each pharma contract sales submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each pharma contract sales submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading pharma contract sales markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- What are the pharma contract sales projects for these leading companies?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of pharma contract sales projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the pharma contract sales market?
- Where is the pharma contract sales market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the pharma contract sales market today, and over the next 10 years:
- This 399-page report provides 179 tables and 228 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
- Forecasts to 2035 and other analysis reveal commercial prospects
- In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
- You will find original analysis, with business outlooks and developments.
- Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising pharma contract sales prices and recent developments.
How will the Pharma Contract Sales Market report help you?
In summary, the 390+ page report provides you with the following knowledge:- Revenue forecasts to 2035 for Pharma Contract Sales Market, with forecasts for services, therapeutic areas, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 27 key national markets - See forecasts for the Pharma Contract Sales Market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 24 of the major companies involved in the Pharma Contract Sales Market.
- Find quantitative and qualitative analysis with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.
Table of Contents
1 Report Overview
3 Market Overview
4 Pharma Contract Sales Market Analysis by Services
5 Pharma Contract Sales Market Analysis by Therapeutic Areas
6 Pharma Contract Sales Market Analysis by End-users
7 Pharma Contract Sales Market Analysis by Region
8 North America Pharma Contract Sales Market Analysis
9 Europe Pharma Contract Sales Market Analysis
10 Asia Pharma Contract Sales Market Analysis
11 Latin America Pharma Contract Sales Market Analysis
12 MEA Pharma Contract Sales Market Analysis
13 Company Profiles
14 Conclusion and Recommendations
List of Tables
Companies Mentioned
- Amplity, Inc.
- Apodi
- Cencora, Inc.
- CMIC HOLDINGS Co., LTD.
- EPS Corporation
- EVERSANA
- Granard Pharmaceutical Sales & Marketing
- GTS Solution
- ICON plc
- Inizio
- IQVIA Inc.
- MaBiCo
- Marvecs GmbH
- Mednext Pharma Pvt. Ltd.
- ONCALL, LLC
- Peak Pharma Solutions Inc.
- Promoveo Health
- QFR Solutions
- Sales Focus Inc.
- Sales Partnerships, Inc.
- SOFIP
- Syneos Health
- Uniphar | Global Sourcing
- VANGUARD PHARMA, LLC
- Adobe
- Bayer
- Blackstone Inc.
- Elliott Investment Management
- EPPCO
- Evoke Pharma
- Fette Compacting
- Forever Oceans
- Fosun Pharma USA Inc.
- Iterum Therapeutics
- Lyfegen
- NVIDIA
- Nye Health
- PharmaLex Holding GmbH
- Pinnacle Sourcing
- Public Health Expertise (PHE)
- Tonix Pharmaceuticals
- Veeva Systems
- Veritas Capital
- Waltz Health
- Webster Equity Partners
- American Association of Pharmaceutical Scientists (AAPS)
- Association for Accessible Medicines (AAM)
- Association of the British Pharmaceutical Industry (ABPI)
- Association of the European Self-Care Industry (AESGP)
- Biotechnology Innovation Organization (BIO)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Indian Pharmaceutical Association (IPA)
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
- International Society for Pharmaceutical Engineering (ISPE)
- Kyushu University Hospital
- Mayapada Hospital
- Moffitt Cancer Center
- National Cancer Center Hospital, Japan
- National Health Service (NHS)
- Organisation of Pharmaceutical Producers of India (OPPI)
- Parenteral Drug Association (PDA)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Ritsumeikan University College of Pharmaceutical Sciences
